Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial
-
Published:2024-01
Issue:1
Volume:35
Page:118-129
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Ladetto M., Tavarozzi R.ORCID, Zanni M., Evangelista A., Ferrero S., Tucci A., Botto B., Bolis S., Volpetti S., Zilioli V.R., Puccini B., Arcari A., Pavone V., Gaidano G.ORCID, Corradini P., Tani M., Cavallo F., Milone G., Ghiggi C., Pinto A., Pastore D.ORCID, Ferreri A.J.M.ORCID, Latte G., Patti C., Re F., Benedetti F., Luminari S., Pennese E., Bossi E.ORCID, Boccomini C., Anastasia A., Bottelli C., Ciccone G., Vitolo U.
Subject
Oncology,Hematology
Reference38 articles.
1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms;Swerdlow;Blood,2016 2. Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?;Tellier;Blood,2014 3. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups;Batlevi;Blood Cancer J,2020 4. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group 5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
|
|